Emiliem, Inc is a private biotechnology company focused on understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions. The company is particularly interested in diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes. Emiliem is co-owner of:

Elara Bioscience LLC, www.elarabio.com which provides a comprehensive infrastructure designed to support (1) collaborative research applications such as data and document exchange between contract research organizations (CROs) and clients and (2) industrial and environmental toxicology where the portal, ToxPlatformTM, is designed to integrate all relevant and available chemical-toxicity resources, with functionality broadly applicable to human health from chemical exposures.